4D pharma today announced it registered with the SEC to list on the Nasdaq under the symbol ‘LBPS’ following its proposed merger with Longevity Acquisition. The deal is expected to close in Q1 2021, pending shareholder approval. Shareholders earlier this week voted to grant the SPAC an extension until May 2021 to close a deal. Longevity has filed a preliminary proxy on the proposed combination. Read more.
Related Posts
Spartan IV Drops Deal Size 25% Ahead of $300M IPO
Spartan IV will target opportunities in the energy value chain aligned with energy transition, storage and sustainability.
Decarbonization Plus Acquisition II Sets Vote Date on Tritium Deal
As announced in May, the transaction is anticipated to generate gross proceeds of up to approximately $403 million.
Ascendant Digital Files Investor Presentation on MarketWise Deal
The presentation highlights MarketWise, formerly known as Beacon Street Group, a multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors.
Decarbonization Plus Acquisition II Stockholders Approve Tritium Merger
Redemptions ahead of the vote erased $349.3 million from the SPAC's trust, according to an 8-K filing. The SPAC raised $350 million in a march 2021 IPO.